Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ACUT
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.22
N/A
-0.09
vs -0.05
Q1.23
N/A
-0.07
vs -0.08
Q2.23
N/A
-0.03
vs -0.10
Q3.23
N/A
-0.05
vs -0.08
Q2.24
+4187%
1.34
vs -0.03
Q3.24
+3022%
1.54
vs -0.05
Sales Growth
YoY
Current
Estimates
Q4.22
NA
NA vs NA
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Return on Equity
QoQ
Q1.22
-29%
-0.29
vs -1.03
Q2.22
-65%
-0.65
vs -0.29
Q3.22
-113%
-1.13
vs -0.65
Q4.22
+485832%
4.9K
vs -1.13
Q1.23
+264%
2.64
vs 4.9K
Q2.23
+29%
0.29
vs 2.64
Q3.23
+32%
0.32
vs 0.29
Institutionnal Ownership
globenewswire.com
7 hours ago
globenewswire.com
7 hours ago
globenewswire.com
7 hours ago
globenewswire.com
7 hours ago
globenewswire.com
9 hours ago
Relative Strength
ACUT
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
AccuStem Sciences, Inc. operates as a life sciences company focusing on improving outcomes for patients with cancer. It develops StemPrintER technology, a multi-gene prognostic assay to predict the risk of recurrence of Endocrine receptor-positive /HER2- breast cancer; and Spare, a derivative of StemPrintER that combines StemPrintER with two clinical markers. The company is based in New York, New York.
PNK
Unprofitable
Unprofitable
Relative Strenght
Volume Buzz
-89%
Earning Acce
No
Dist 52w H.
42%Quote Panel
Key Metrics
Forecast
No Data Available
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How ACUT compares to sector?